Eruptive papules during efalizumab (anti-CD I Ia) therapy of psoriasis vulgaris: a case series

Background: Newer biological therapies for moderate-to-severe psoriasis are being used more frequently, but unexpected effects may occur. Case presentations: We present a group of 15 patients who developed inflammatory papules while on efalizumab therapy (Raptiva, Genentech Inc, anti-CD I I a). Immunohistochemistry showed that there were increased CD11b(+), CD11c(+) and iNOS(+) cells (myeloid leukocytes) in the papules, with relatively few CD3(+) T cells. While efalizumab caused a decreased expression of CDI I a on T cells, other circulating leukocytes from patients receiving this therapy often showed increased CDI I b and CD I I c. In the setting of an additional stimulus such as skin trauma, this may predispose to increased trafficking into the skin using these alternative beta 2 integrins. In addition, there may be impaired immune synapse formation, limiting the development of these lesions to small papules. There is little evidence for these papular lesions being "allergic" in nature as there are few eosinophils on biopsy, and they respond to minimal or no therapy even if efalizumab is continued. Conclusion: We hypothesize that these papules may represent a unique type of "mechanistic" inflammatory reaction, seen only in the context of drug-induced CD I I a blockade, and not during the natural disease process.